An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.
Identifieur interne : 001128 ( PubMed/Corpus ); précédent : 001127; suivant : 001129An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.
Auteurs : Yasuko Hatta ; Masato Hatta ; Pamuk Bilsel ; Gabriele Neumann ; Yoshihiro KawaokaSource :
- Vaccine [ 1873-2518 ] ; 2011.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Dogs, Female, HEK293 Cells, Humans, Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H1N1 Subtype (pathogenicity), Influenza Vaccines (immunology), Mice, Mice, Inbred BALB C, Mutation, Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Vaccines, Attenuated (immunology), Viral Matrix Proteins (genetics), Viral Matrix Proteins (immunology), Virulence, Virus Cultivation.
- MESH :
- chemical , blood : Antibodies, Viral.
- chemical , genetics : Viral Matrix Proteins.
- chemical , immunology : Antibodies, Viral, Influenza Vaccines, Vaccines, Attenuated, Viral Matrix Proteins.
- genetics : Influenza A Virus, H1N1 Subtype.
- immunology : Influenza A Virus, H1N1 Subtype, Orthomyxoviridae Infections.
- pathogenicity : Influenza A Virus, H1N1 Subtype.
- prevention & control : Orthomyxoviridae Infections.
- Animals, Dogs, Female, HEK293 Cells, Humans, Mice, Mice, Inbred BALB C, Mutation, Virulence, Virus Cultivation.
Abstract
The 2009 influenza pandemic brought home the importance of vaccines in infection control. Previously, we demonstrated an M2 cytoplasmic tail mutant H5N1 influenza virus could serve as a live-attenuated vaccine. Here, we adapted that strategy, generating a mutant pandemic (H1N1) 2009 virus that grew well in cell culture, but replicated less well in mice than did wild-type virus. The mutant virus elicited sterile immunity in mice, completely protecting them from challenge with a pandemic (H1N1) 2009 virus. Our results indicate that M2 cytoplasmic tail mutants are suitable for live-attenuated vaccines against pandemic viruses.
DOI: 10.1016/j.vaccine.2011.01.023
PubMed: 21272601
Links to Exploration step
pubmed:21272601Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.</title><author><name sortKey="Hatta, Yasuko" sort="Hatta, Yasuko" uniqKey="Hatta Y" first="Yasuko" last="Hatta">Yasuko Hatta</name><affiliation><nlm:affiliation>Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hatta, Masato" sort="Hatta, Masato" uniqKey="Hatta M" first="Masato" last="Hatta">Masato Hatta</name></author><author><name sortKey="Bilsel, Pamuk" sort="Bilsel, Pamuk" uniqKey="Bilsel P" first="Pamuk" last="Bilsel">Pamuk Bilsel</name></author><author><name sortKey="Neumann, Gabriele" sort="Neumann, Gabriele" uniqKey="Neumann G" first="Gabriele" last="Neumann">Gabriele Neumann</name></author><author><name sortKey="Kawaoka, Yoshihiro" sort="Kawaoka, Yoshihiro" uniqKey="Kawaoka Y" first="Yoshihiro" last="Kawaoka">Yoshihiro Kawaoka</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21272601</idno><idno type="pmid">21272601</idno><idno type="doi">10.1016/j.vaccine.2011.01.023</idno><idno type="wicri:Area/PubMed/Corpus">001128</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001128</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.</title><author><name sortKey="Hatta, Yasuko" sort="Hatta, Yasuko" uniqKey="Hatta Y" first="Yasuko" last="Hatta">Yasuko Hatta</name><affiliation><nlm:affiliation>Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hatta, Masato" sort="Hatta, Masato" uniqKey="Hatta M" first="Masato" last="Hatta">Masato Hatta</name></author><author><name sortKey="Bilsel, Pamuk" sort="Bilsel, Pamuk" uniqKey="Bilsel P" first="Pamuk" last="Bilsel">Pamuk Bilsel</name></author><author><name sortKey="Neumann, Gabriele" sort="Neumann, Gabriele" uniqKey="Neumann G" first="Gabriele" last="Neumann">Gabriele Neumann</name></author><author><name sortKey="Kawaoka, Yoshihiro" sort="Kawaoka, Yoshihiro" uniqKey="Kawaoka Y" first="Yoshihiro" last="Kawaoka">Yoshihiro Kawaoka</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (immunology)</term><term>Dogs</term><term>Female</term><term>HEK293 Cells</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (genetics)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza A Virus, H1N1 Subtype (pathogenicity)</term><term>Influenza Vaccines (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mutation</term><term>Orthomyxoviridae Infections (immunology)</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Vaccines, Attenuated (immunology)</term><term>Viral Matrix Proteins (genetics)</term><term>Viral Matrix Proteins (immunology)</term><term>Virulence</term><term>Virus Cultivation</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Viral Matrix Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term><term>Viral Matrix Proteins</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dogs</term><term>Female</term><term>HEK293 Cells</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mutation</term><term>Virulence</term><term>Virus Cultivation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The 2009 influenza pandemic brought home the importance of vaccines in infection control. Previously, we demonstrated an M2 cytoplasmic tail mutant H5N1 influenza virus could serve as a live-attenuated vaccine. Here, we adapted that strategy, generating a mutant pandemic (H1N1) 2009 virus that grew well in cell culture, but replicated less well in mice than did wild-type virus. The mutant virus elicited sterile immunity in mice, completely protecting them from challenge with a pandemic (H1N1) 2009 virus. Our results indicate that M2 cytoplasmic tail mutants are suitable for live-attenuated vaccines against pandemic viruses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21272601</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>09</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.</ArticleTitle><Pagination><MedlinePgn>2308-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2011.01.023</ELocationID><Abstract><AbstractText>The 2009 influenza pandemic brought home the importance of vaccines in infection control. Previously, we demonstrated an M2 cytoplasmic tail mutant H5N1 influenza virus could serve as a live-attenuated vaccine. Here, we adapted that strategy, generating a mutant pandemic (H1N1) 2009 virus that grew well in cell culture, but replicated less well in mice than did wild-type virus. The mutant virus elicited sterile immunity in mice, completely protecting them from challenge with a pandemic (H1N1) 2009 virus. Our results indicate that M2 cytoplasmic tail mutants are suitable for live-attenuated vaccines against pandemic viruses.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hatta</LastName><ForeName>Yasuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatta</LastName><ForeName>Masato</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bilsel</LastName><ForeName>Pamuk</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kawaoka</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN266200700006C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN266200700010C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI069274</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI069274-05</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C488937">M2 protein, Influenza A virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014776" MajorTopicYN="N">Virus Cultivation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>08</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21272601</ArticleId><ArticleId IdType="pii">S0264-410X(11)00051-X</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2011.01.023</ArticleId><ArticleId IdType="pmc">PMC3132197</ArticleId><ArticleId IdType="mid">NIHMS272765</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell. 1992 May 15;69(4):577-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1375129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1992 May 1;69(3):517-28</Citation><ArticleIdList><ArticleId IdType="pubmed">1374685</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(6):3595-605</Citation><ArticleIdList><ArticleId IdType="pubmed">15731254</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Jun;80(11):5233-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16699003</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Aug;80(16):8178-89</Citation><ArticleIdList><ArticleId IdType="pubmed">16873274</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Mar;82(5):2486-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18160446</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Jun;83(11):5947-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19321619</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Jun 18;360(25):2605-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19423869</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Aug 20;460(7258):1021-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19672242</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Sep 24;361(13):1260-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19776407</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2009 Nov 10;181(10):673-80</Citation><ArticleIdList><ArticleId IdType="pubmed">19825923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Feb 1;201(3):354-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20039806</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010;6(8):e1001034</Citation><ArticleIdList><ArticleId IdType="pubmed">20700447</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Nov 18;363(21):2036-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21083388</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2001 Sep;65(1):171-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11505460</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2001 Dec;146(12):2275-89</Citation><ArticleIdList><ArticleId IdType="pubmed">11811679</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1984 Feb;43(2):457-62</Citation><ArticleIdList><ArticleId IdType="pubmed">6693167</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345-50</Citation><ArticleIdList><ArticleId IdType="pubmed">10430945</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001128 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001128 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21272601
|texte= An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21272601" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |